Why the study?
The progression of renal failure to ESRD despite treatment with systemic RAS inhibitors indicates the presence of factors other than Ang II.
Design
Review
Authors
Loading...
Supports adjunctive pathway research beyond RAS inhibition in progressing diabetic nephropathy; leaves open identification of dominant non-Angiotensin II targets.
The review highlights that factors beyond Angiotensin II contribute to the progression of diabetic nephropathy, despite the use of ACE inhibitors or ARBs.
Bahreini et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: